Randomized Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck

M.D. Mix; M. Jameson; M. Tills; S. Dibaj; A. Groman; W. Jaggernauth; Y. Rustum; A.K. Singh

doi:10.1016/j.ijrobp.2013.06.1234

Randomized Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2013.06.1234 ◽

2013 ◽

Vol 87 (2) ◽

pp. S466-S467 ◽

Cited By ~ 2

Author(s):

M.D. Mix ◽

M. Jameson ◽

M. Tills ◽

S. Dibaj ◽

A. Groman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Multicenter Phase

Download Full-text

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30737-3 ◽

2021 ◽

Vol 22 (4) ◽

pp. 450-462

Author(s):

Nancy Y Lee ◽

Robert L Ferris ◽

Amanda Psyrri ◽

Robert I Haddad ◽

Makoto Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

Standard Of Care ◽

Advanced Squamous Cell Carcinoma ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase

Download Full-text

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)71200-8 ◽

2015 ◽

Vol 16 (2) ◽

pp. 221-232 ◽

Cited By ~ 96

Author(s):

Jordi Giralt ◽

Jose Trigo ◽

Sandra Nuyts ◽

Mahmut Ozsahin ◽

Krzysztof Skladowski ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)71198-2 ◽

2015 ◽

Vol 16 (2) ◽

pp. 208-220 ◽

Cited By ~ 94

Author(s):

Ricard Mesía ◽

Michael Henke ◽

Andre Fortin ◽

Heikki Minn ◽

Alejandro Cesar Yunes Ancona ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

A phase 2 trial of inductionnab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck

Cancer ◽

10.1002/cncr.27741 ◽

2012 ◽

Vol 119 (4) ◽

pp. 766-773 ◽

Cited By ~ 18

Author(s):

Douglas Adkins ◽

Jessica Ley ◽

Kathryn Trinkaus ◽

Wade Thorstad ◽

James Lewis ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Phase 2 Trial

Download Full-text

Faculty Opinions recommendation of Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739862510.793585610 ◽

2021 ◽

Author(s):

Sandra Nuyts ◽

Heleen Bollen

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

Standard Of Care ◽

Advanced Squamous Cell Carcinoma ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase

Download Full-text

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30064-5 ◽

2017 ◽

Vol 18 (3) ◽

pp. 323-335 ◽

Cited By ~ 90

Author(s):

Denis Soulières ◽

Sandrine Faivre ◽

Ricard Mesía ◽

Éva Remenár ◽

Shau-Hsuan Li ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Metastatic Squamous Cell Carcinoma

Download Full-text

Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

Oral Oncology ◽

10.1016/j.oraloncology.2021.105192 ◽

2021 ◽

Vol 115 ◽

pp. 105192

Author(s):

Douglas R. Adkins ◽

Jin-Ching Lin ◽

Assuntina Sacco ◽

Jessica Ley ◽

Peter Oppelt ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Human Papillomavirus ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial

Annals of Oncology ◽

10.1016/j.annonc.2021.07.008 ◽

2021 ◽

Author(s):

B.G.M. Hughes ◽

E. Munoz-Couselo ◽

L. Mortier ◽

Å. Bratland ◽

R. Gutzmer ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Locally Advanced ◽

Cutaneous Squamous Cell Carcinoma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase

Download Full-text

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(20)30327-2 ◽

2020 ◽

Vol 21 (9) ◽

pp. 1173-1187 ◽

Cited By ~ 6

Author(s):

Xu-Shan Sun ◽

Yungan Tao ◽

Christophe Le Tourneau ◽

Yoann Pointreau ◽

Christian Sire ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

High Risk ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

High Dose ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Study

Download Full-text

Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study

Annals of Oncology ◽

10.1093/annonc/mdz394.062 ◽

2019 ◽

Vol 30 ◽

pp. v902 ◽

Cited By ~ 2

Author(s):

J. Bourhis ◽

X. Sun ◽

Y. Pointreau ◽

C. Sire ◽

C. Le Tourneau ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

High Risk ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

High Dose ◽

Advanced Squamous Cell Carcinoma ◽

Double Blind ◽

Randomized Phase Ii ◽

Risk Patients

Download Full-text